<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002273</url>
  </required_header>
  <id_info>
    <org_study_id>029C</org_study_id>
    <secondary_id>ICM 1288</secondary_id>
    <nct_id>NCT00002273</nct_id>
  </id_info>
  <brief_title>A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS</brief_title>
  <official_title>Double-Blind, Placebo-Controlled Study of Intravenous Ganciclovir (DHPG) for Cytomegalovirus Colitis in Patients With Acquired Immune Deficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To attempt to demonstrate the efficacy of ganciclovir (DHPG) treatment of cytomegalovirus&#xD;
      (CMV) colitis in AIDS patients by evaluating both clinical and virologic parameters. To&#xD;
      determine acceptability and the safety profile of a 2-week course of intravenous (IV) DHPG&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Colitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  An underlying diagnosis of AIDS by CDC surveillance definition (group IV, category c-1&#xD;
             or subgroup D only).&#xD;
&#xD;
          -  Colitis manifested clinically by diarrhea.&#xD;
&#xD;
          -  Colon biopsy demonstrating a typical histologic picture of cytomegalovirus (CMV)&#xD;
             disease.&#xD;
&#xD;
          -  Cultures for CMV from blood and urine should be obtained within 1 week of study entry&#xD;
             but need not be positive prior to entry. (A positive culture is needed for final&#xD;
             inclusion in AN.)&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Topical acyclovir.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of chronic or acute liver disease.&#xD;
&#xD;
          -  History of significant mental illness.&#xD;
&#xD;
          -  Life expectancy &lt; 1 month.&#xD;
&#xD;
          -  Presence of any cause of colitis other than cytomegalovirus (CMV). (The following&#xD;
             tests must be negative:&#xD;
&#xD;
          -  Stool culture for enteric bacterial pathogens, stool exam for ova and parasites, stool&#xD;
             exam for cryptosporidia, stool exam for AFB.) Colitis that is so severe that it would&#xD;
             be against the patient's best interest to be treated with placebo for 2 weeks prior to&#xD;
             being eligible to receive ganciclovir (DHPG) on a &quot;compassionate&quot; use basis. Patients&#xD;
             with a colitis of this severity should be treated with DHPG on &quot;compassionate&quot; use&#xD;
             basis.&#xD;
&#xD;
          -  Presence of clinically significant extra-colonic active CMV disease of retina or&#xD;
             visceral organs (which could progress during the no-treatment period).&#xD;
&#xD;
          -  Presence of significant renal disease resulting in any decrement of creatinine&#xD;
             clearance from normal.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any other investigational drug, whether or not as part of a formal clinical study.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of chronic or acute liver disease.&#xD;
&#xD;
          -  History of significant mental illness.&#xD;
&#xD;
          -  Life expectancy &lt; 1 month.&#xD;
&#xD;
          -  Presence of any cause of colitis other than cytomegalovirus (CMV). (The following&#xD;
             tests must be negative:&#xD;
&#xD;
          -  Stool culture for enteric bacterial pathogens, stool exam for ova and parasites, stool&#xD;
             exam for cryptosporidia, stool exam for AFB.) Colitis that is so severe that it would&#xD;
             be against the patient's best interest to be treated with placebo for 2 weeks prior to&#xD;
             being eligible to receive ganciclovir (DHPG) on a &quot;compassionate&quot; use basis. Patients&#xD;
             with a colitis of this severity should be treated with DHPG on &quot;compassionate&quot; use&#xD;
             basis.&#xD;
&#xD;
          -  Presence of clinically significant extra-colonic active CMV disease of retina or&#xD;
             visceral organs (which could progress during the no-treatment period).&#xD;
&#xD;
          -  Presence of significant renal disease resulting in any decrement of creatinine&#xD;
             clearance from normal.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 days of study entry:&#xD;
&#xD;
          -  Nucleoside analogs.&#xD;
&#xD;
          -  Excluded within 1 week of study entry:&#xD;
&#xD;
          -  Antimetabolites or interferon.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Roche Global Development - Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dieterich DT, Kotler DP, Busch DF, Crumpacker C, Du Mond C, Dearmand B, Buhles W. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis. 1993 Feb;167(2):278-82. doi: 10.1093/infdis/167.2.278.</citation>
    <PMID>8380610</PMID>
  </reference>
  <verification_date>September 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Colitis</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

